---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-24-000105"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:20:44.259173+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kiora reports Q2 net loss $2.2M, cash $27.8M; advancing two Phase 2 retinal trials

## Summary
- Q2 revenue $20K (grant); net R&D expense $0.9M after $1.1M TOI reimbursement credits.
- Cash, equivalents and short-term investments $27.8M; plus receivables/Tax credits $3.7M; runway into 2027.
- Phase 2 ABACUS-2 trial of KIO-301 for retinitis pigmentosa design finalized; initiation expected 2H 2024.
- Phase 2 CLARITY trial of KIO-104 for retinal inflammation planned to start 1H 2025, building on Phase 1b.
- Melissa Tosca promoted to CFO; Lisa Walters-Hoffert appointed to Board of Directors.

## SEC filing metadata
- accession: 0001372514-24-000105
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000105/0001372514-24-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000105/kprx-20240809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-24-000105
- JSON: https://secwatch.observer/filing/0001372514-24-000105.json
- Plain text: https://secwatch.observer/filing/0001372514-24-000105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.